The nurse is caring for a client with hypertension, gastroesophageal reflux, and osteoarthritis. While performing a bedside assessment the nurse observes the client is alert and oriented to person, place, time, and situation, but is exhibiting signs of jaundice. The nurse should notify the healthcare provider (HCP) about which scheduled medication?

A. Omeprazole: Omeprazole, a proton pump inhibitor, is primarily metabolized by the liver, but hepatotoxicity is rare. While liver function should be monitored in clients with existing liver disease, occasional jaundice is not commonly linked to omeprazole use. B. Acetaminophen: Acetaminophen is metabolized in the liver and can cause hepatotoxicity, especially with chronic use or higher-than-recommended doses. The observation of jaundice in a client taking acetaminophen is a significant clinical finding that may indicate liver injury. Prompt reporting to the healthcare provider is essential to prevent further hepatic damage. C. Prednisone: Prednisone is a corticosteroid metabolized by the liver, but jaundice is not a common adverse effect. Its main risks include immunosuppression, hyperglycemia, and fluid retention. While liver monitoring is sometimes warranted, immediate jaundice is more concerning with hepatotoxic medications like acetaminophen. D. Captopril: Captopril is an ACE inhibitor used for hypertension. Hepatotoxicity is rare, and jaundice is not a common adverse effect. It is not the primary concern in this scenario compared with acetaminophen, which directly affects liver function.